Compare Tilray Brands Inc (TLRY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs Zoetis Inc — how do they compare? Tilray Brands Inc trades at $4.75 (market cap $649.42M), while Zoetis Inc trades at $73.68 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 48× Tilray Brands Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| TLRY | ZTS | |
|---|---|---|
Market Cap | $649.42M | $31.14B |
Sector | Health | Health |
52-Week High | $21.00 | $156.76 |
52-Week Low | $3.88 | $71.91 |
Enterprise Value | $816.55M | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.68, up 5.88% today, amid bullish technical signals and news-driven momentum. The company reported record fiscal 2026 revenue of $915 million but posted a net loss of $121 million, with profitability challenges persisting. Recent developments include new product launches and partnerships, while analyst sentiment remains mixed with a majority hold rating.
Outlook hinges on revenue growth and margin improvement, but risks include sustained losses, high debt, and competitive pressures. The stock offers speculative appeal if execution improves, yet volatility and dilution concerns warrant caution for investors.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
